Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children.

Fiche publication

Date publication

octobre 2022

Journal

Clinical ophthalmology (Auckland, N.Z.)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DORY Anne

Tous les auteurs :
Bourcier T, Dory A, Dormegny L, Alcazar J, Gaucher D, Sauer A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36304991

Résumé

Vernal keratoconjunctivitis (VKC) is an inflammatory condition in children that can cause severe eye complications. Treatment is based on corticosteroid therapy during flare-ups, then antihistamines and cyclosporine in calmer periods. The dosage and posology of cyclosporine are subject to debate.